Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and Cabergoline are shown to effectively inhibit prolactin secretion with improved efficacy over Bromocriptine. These drugs are effective in patients who are intolerant or resistant to Bromocriptine. Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.
用于治疗伴有高泌乳素血症的帕金森病,血催乳激素过多症(原发的或者是因分泌催乳激素的垂体微小腺瘤或巨腺瘤),也用于治疗肢端肥大症。
Gyneacology Rigshospitalet, Copenhagen, Denmark
Gabinet Lekarski Specjalistyczny SONUS, Warsaw, Poland
Specjalistyczny Gabinet Lekarski, Warsaw, Poland
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Arkansas Primary Care Clinic, Little Rock, Arkansas, United States
Instituto Valenciano de Infertilidad, Valencia, Spain
IVI Bilbao, Paseo Landabarri, 1, Leioa-Bizkaia, Spain
IVI Sevilla, Avda. República Argentina, 58, Sevilla, Spain
IVI Barcelona, Ronda General Mitre, 14, Barcelona, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.